VolitionRx Limited (NYSE American:VNRX), a US-based multinational epigenetics company, announced on Thursday that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants.

Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and warrants offered in the offering at the public offering price, less underwriting discounts and commissions.

All the securities in the offering are being offered by Volition. Final terms will depend on market and other conditions, and Volition noted that there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialisation, working capital and other general corporate purposes, including potential strategic acquisitions.

Newbridge Securities Corporation is acting as the sole book-running manager of the proposed offering.